Prospective assessment of chemotherapy-induced peripheral neuropathy due to weekly paclitaxel in patients with advanced or metastatic breast cancer (CSP-HOR 02 study)
- 17 December 2008
- journal article
- research article
- Published by Springer Science and Business Media LLC in Supportive Care in Cancer
- Vol. 17 (8), 1071-1080
- https://doi.org/10.1007/s00520-008-0550-x
Abstract
No abstract availableKeywords
This publication has 35 references indexed in Scilit:
- Feasibility and validity of the Patient Neurotoxicity Questionnaire during taxane chemotherapy in a phase III randomized trial in patients with breast cancer: N-SAS BC 02Supportive Care in Cancer, 2009
- A Questionnaire Survey of Physicians' Perspectives Regarding the Assessment of Chemotherapy-induced Peripheral Neuropathy in Patients with Breast CancerJapanese Journal of Clinical Oncology, 2008
- A randomized phase III study comparing three anthracycline-free taxane-based regimens, as first line chemotherapy, in metastatic breast cancerBreast Cancer Research and Treatment, 2008
- Weekly Paclitaxel in the Adjuvant Treatment of Breast CancerThe New England Journal of Medicine, 2008
- Putting Evidence Into Practice®: Evidence-Based Interventions for Chemotherapy-Induced Peripheral NeuropathyClinical Journal of Oncology Nursing, 2007
- Integrating Patient-Reported Outcomes Into Cancer Symptom Management Clinical Trials Supported by the National Cancer Institute–Sponsored Clinical Trials NetworksJournal of Clinical Oncology, 2007
- Standardizing Patient-Reported Outcomes Assessment in Cancer Clinical Trials: A Patient-Reported Outcomes Measurement Information System InitiativeJournal of Clinical Oncology, 2007
- Multi‐center assessment of the Total Neuropathy Score for chemotherapy‐induced peripheral neurotoxicityJournal of the Peripheral Nervous System, 2006
- Weekly Administration of Docetaxel and Paclitaxel in Metastatic or Advanced Breast CancerThe Oncologist, 2005
- “Will Weekly Work”? Seems to Be So…Journal of Clinical Oncology, 2005